Radiopharm Theranostics Ltd ADR (RADX) Stock Price, Quote & News

Company Profile

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; a...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9824 5254

Fax: 61 3 9822 7735

Website: www.radiopharmtheranostics.com

Address:

62 Lygon Street, Level 3, Carlton, Australia

Lalalilala Aug. 4 at 2:36 PM

$RADX I know the volume isn't huge, but for the past few days I've noticed that the daily average has been exceeded by 100%... Radio Isotope 25 beat me to it, but I just checked and after an hour of trading, I think 50,000 shares is still a lot, and we haven't seen that often. I bought 1,500 more yesterday and now I have another 1,350 pending at 2.94. We'll see if it goes through or not.

0 · Reply

BogartHumphrey Aug. 4 at 2:28 PM

$RADX trash bullshit. The only red stock in my portfolio everyday. Zacks and their bullshit price targets. Lol

0 · Reply

RadioIsotope25 Aug. 4 at 1:59 PM

$RADX Big buyer

0 · Reply

Ontherag Aug. 3 at 10:36 PM

$RADX We literally have a 500M dollar asset that can make profit in 2-3 years It tells you this market sucks right now

1 · Reply

Ontherag Aug. 3 at 10:35 PM

$RADX Market cap this low with data this great doesn’t make sense

1 · Reply

ZacksSCR Aug. 3 at 7:15 PM

$RADX: RAD101 Topline & FY:26 Cash Flows https://buff.ly/n2s4tSj

0 · Reply

RadioIsotope25 Aug. 3 at 6:10 PM

$RADX Based on what is publicly known today, I think the probability of some form of RAD101 transaction (licensing, co-development, or regional partnership) is meaningfully better than it was before the Phase 2b data. My estimate is: Any licensing/partnership within the next 12 months: 60–75% Deal before Phase 3 starts (targeted for Q4 2026): 40–60% Full acquisition driven primarily by RAD101: 15–30%

0 · Reply

RadioIsotope25 Aug. 3 at 5:39 PM

$RADX Asset purchases are much quicker than mergers.

1 · Reply

RadioIsotope25 Aug. 3 at 3:56 PM

$RADX Thick amount of buyers around these prices

2 · Reply

RadioIsotope25 Aug. 3 at 3:47 PM

Radiopharmaceutical company Curium has agreed to buy peer Lantheus Holdings in a deal worth up to $8 billion, as the private equity-backed firm looks to expand … Source: Reuters $RADX https://www.reuters.com/legal/transactional/curium-buy-lantheus-up-8-billion-deal-2026-08-03/

1 · Reply

Radiopharm Theranostics (RADX) Secures $4.1M in Direct Offering

2026-07-24T11:30:24.000Z - 11 days ago

Radiopharm announces $4.1M registered direct offering

Fri, 24 Jul 2026 07:15:00 -0400 - 11 days ago

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

2026-07-22T15:38:29.000Z - 12 days ago

Radiopharm Theranostics Reports Positive Trial Updates For RAD101 And RAD204

Wed, 22 Jul 2026 07:05:00 -0400 - 13 days ago

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

Wed, 22 Jul 2026 07:00:00 -0400 - 13 days ago

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

2026-07-22T07:57:15.000Z - 13 days ago

Radiopharm Reports Positive Phase 2b Data For RAD101 In Brain Metastases Diagnosis

2026-07-22T00:00:11.000Z - 13 days ago

Radiopharm Theranostics trading halted, news pending

2026-06-04T10:10:20.000Z - 2 months ago

Radiopharm initiated with a Buy at H.C. Wainwright

Apr 28, 2026, 12:00 PM EDT - 3 months ago

Radiopharm Theranostics Transcript: Deutsche Bank ADR Virtual Investor Conference

Apr 28, 2026, 12:00 PM EDT - 3 months ago

Radiopharm Theranostics Slides: Deutsche Bank ADR Virtual Investor Conference

Apr 23, 2026, 7:00 AM EDT - 3 months ago

Radiopharm Theranostics Reports Business Update

RADX

Apr 22, 2026, 6:00 PM EDT - 3 months ago

Radiopharm Theranostics Earnings release: Q3 2026

2026-04-20T12:08:59.000Z - 3 months ago

Radiopharm announces new data from Phase 0/1 HEAT trial

2026-04-08T11:45:06.000Z - 4 months ago

Radiopharm gets DSMC recommendation to advance 177Lu-RAD202 to next dose

Apr 7, 2026, 7:00 AM EDT - 4 months ago

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

RADX

2026-03-27T15:36:04.000Z - 4 months ago

Biotech Alert: Searches spiking for these stocks today

SMMT SPRB

Mar 27, 2026, 7:00 AM EDT - 4 months ago

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer

RADX

2026-03-26T15:41:23.000Z - 4 months ago

Biotech Alert: Searches spiking for these stocks today

Mar 24, 2026, 6:00 PM EDT - 4 months ago

Radiopharm Theranostics Transcript: Study result

Mar 24, 2026, 6:00 PM EDT - 4 months ago

Radiopharm Theranostics Press release: Study result

Mar 24, 2026, 5:30 PM EDT - 4 months ago

Radiopharm Theranostics Transcript: NWR Virtual Healthcare Conference

2026-02-24T12:54:28.000Z - 5 months ago

Radiopharm doses first patient in Phase 1/2a study of BetaBart

Jan 28, 2026, 7:00 AM EST - 6 months ago

Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates

RADX

Jan 27, 2026, 6:00 PM EST - 6 months ago

Radiopharm Theranostics Earnings release: Q2 2026

Jan 21, 2026, 9:05 AM EST - 6 months ago

Radiopharm Theranostics Transcript: Emerging Growth Conference 89

2026-01-12T12:41:55.000Z - 7 months ago

Radiopharm increases ownership in Radiopharm Ventures to 87.5%

Jan 12, 2026, 7:00 AM EST - 7 months ago

RAD Increases Ownership in Radiopharm Ventures to 87.5%

RADX

2025-12-17T16:40:22.000Z - 8 months ago

Biotech Alert: Searches spiking for these stocks today

AIM

2025-12-17T13:50:36.000Z - 8 months ago

Radiopharm price target raised to $15 from $12 at Maxim

Dec 17, 2025, 7:00 AM EST - 8 months ago

Radiopharm Theranostics Registration statement: Registration filing

2025-12-16T17:10:30.000Z - 8 months ago

Biotech Alert: Searches spiking for these stocks today

2025-12-16T13:00:34.000Z - 8 months ago

Radiopharm price target raised to $16 from $13 at B. Riley

Dec 16, 2025, 7:00 AM EST - 8 months ago

Radiopharm Theranostics Registration statement: Registration filing

Dec 15, 2025, 6:00 PM EST - 8 months ago

Radiopharm Theranostics Transcript: Study Update

Dec 15, 2025, 6:00 PM EST - 8 months ago

Radiopharm Theranostics Press release: Study Update

2025-12-15T12:34:24.000Z - 8 months ago

Why Is Radiopharm Theranostics Stock (RADX) Up Today?

2025-12-15T12:05:27.000Z - 8 months ago

Radiopharm achieves primary endpoint in 92% of patients in RAD 101 trial

Dec 15, 2025, 7:00 AM EST - 8 months ago

Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

RADX

2025-11-26T14:20:48.000Z - 8 months ago

Radiopharm price target lowered to $13 from $15 at B. Riley

Nov 19, 2025, 6:00 PM EST - 9 months ago

Radiopharm Theranostics Slides: FY 2025

2025-11-18T14:45:09.000Z - 9 months ago

Radiopharm receives approval to initiate Phase 1 trial of RAD 402

2025-11-17T13:21:04.000Z - 9 months ago

Radiopharm announces 50% enrollment in Phase 2b trial of RAD101

2025-11-12T13:35:22.000Z - 9 months ago

Radiopharm starts enrollment of third cohort in Phase 1 trial of 177Lu-RAD204

Nov 4, 2025, 12:30 PM EST - 9 months ago

Radiopharm Theranostics Transcript: Deutsche Bank ADR Virtual Investor Conference 2025

Oct 27, 2025, 7:00 PM EDT - 10 months ago

Radiopharm Theranostics Earnings release: Q1 2026

2025-10-20T12:10:31.000Z - 10 months ago

Radiopharm provides update on pipeline of clinical programs

Oct 20, 2025, 7:30 AM EDT - 10 months ago

Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan

RADX

Oct 19, 2025, 6:00 PM EDT - 10 months ago

Radiopharm Theranostics Slides: Investor Presentation

Sep 24, 2025, 8:30 PM EDT - 11 months ago

Radiopharm Theranostics Transcript: KOL Event

Sep 1, 2025, 8:30 PM EDT - 1 year ago

Radiopharm Theranostics Transcript: KOL Event

Aug 26, 2025, 8:30 PM EDT - 1 year ago

Radiopharm Theranostics Transcript: KOL Event

Aug 26, 2025, 8:30 PM EDT - 1 year ago

Radiopharm Theranostics Press release: KOL Event

Tue, 29 Jul 2025 07:30:00 -0400 - 1 year ago

Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update

Jul 28, 2025, 6:00 PM EDT - 1 year ago

Radiopharm Theranostics Annual report: Q4 2025

Jul 28, 2025, 6:00 PM EDT - 1 year ago

Radiopharm Theranostics Earnings release: Q4 2025

Tue, 22 Jul 2025 08:00:00 -0400 - 1 year ago

Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

Mon, 02 Jun 2025 08:00:00 -0400 - 1 year ago

Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake

Mon, 19 May 2025 08:00:00 -0400 - 1 year ago

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

Apr 28, 2025, 6:00 PM EDT - 1 year ago

Radiopharm Theranostics Earnings release: Q3 2025

Mar 18, 2025, 6:40 PM EDT - 1 year ago

Radiopharm Theranostics Transcript: NWR Virtual Healthcare Conference

Mar 4, 2025, 9:10 AM EST - 1 year ago

Radiopharm Theranostics Transcript: TD Cowen 45th Annual Healthcare Conference

Jan 29, 2025, 6:00 PM EST - 1 year ago

Radiopharm Theranostics Earnings release: Q2 2025

Mon, 30 Dec 2024 08:00:00 -0500 - 1 year ago

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

Fri, 20 Dec 2024 08:00:00 -0500 - 1 year ago

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Dec 5, 2024, 7:00 AM EST - 1 year ago

Radiopharm Theranostics Registration statement: Registration filing

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Radiopharm Theranostics Earnings release: Q1 2025

Sep 30, 2024, 3:30 AM EDT - 2 years ago

Radiopharm Theranostics Annual report: H2 2024

Thu, 19 Sep 2024 12:00:00 -0400 - 2 years ago

Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of Radiopharm Theranostics Limited

Lalalilala Aug. 4 at 2:36 PM

0 · Reply

BogartHumphrey Aug. 4 at 2:28 PM

$RADX trash bullshit. The only red stock in my portfolio everyday. Zacks and their bullshit price targets. Lol

0 · Reply

RadioIsotope25 Aug. 4 at 1:59 PM

$RADX Big buyer

0 · Reply

Ontherag Aug. 3 at 10:36 PM

$RADX We literally have a 500M dollar asset that can make profit in 2-3 years It tells you this market sucks right now

1 · Reply

Ontherag Aug. 3 at 10:35 PM

$RADX Market cap this low with data this great doesn’t make sense

1 · Reply

ZacksSCR Aug. 3 at 7:15 PM

$RADX: RAD101 Topline & FY:26 Cash Flows https://buff.ly/n2s4tSj

0 · Reply

RadioIsotope25 Aug. 3 at 6:10 PM

0 · Reply

RadioIsotope25 Aug. 3 at 5:39 PM

$RADX Asset purchases are much quicker than mergers.

1 · Reply

RadioIsotope25 Aug. 3 at 3:56 PM

$RADX Thick amount of buyers around these prices

2 · Reply

RadioIsotope25 Aug. 3 at 3:47 PM

1 · Reply

__LucidDreamer__ Aug. 3 at 3:23 PM

$RADX tested my under $3 premarket limit order and got a few shares this morning at $2.99 No idea if stock may plateau lower or not, but sub-$3 feels pretty solid. May cherry-pick down here for a while.

1 · Reply

Lalalilala Aug. 3 at 2:47 PM

$RADX The official closing of the acquisition is normally scheduled for the first half of 2027!! Not today.... I hope a buyer can now make an offer for RADX in its entirety. (I don't care if it's for RAD 101, RAD 204, RAD 202, or the whole company!!) I'm in the process of buying another 1250...

2 · Reply

YungnredE Aug. 3 at 2:28 PM

$RADX reports positive phase 2 news and it's still red... can't make this 💩up. The moment I sell will probably jump 400%.

1 · Reply

RadioIsotope25 Aug. 3 at 2:06 PM

$RADX If they land a deal for rad101 this is a ten dollar bill. Another partial rad204 it’s $20…

0 · Reply

BogartHumphrey Aug. 3 at 2:01 PM

$RADX whole market green except this fucking garbage

0 · Reply

BogartHumphrey Aug. 3 at 1:38 PM

$RADX what a trash turd this company is. Complete train wreck management

0 · Reply

RadioIsotope25 Aug. 3 at 1:14 PM

$RADX Now that Lantheus is acquired hopefully Curium is focused on $RADX now $LNTH $TLX

0 · Reply

RadioIsotope25 Aug. 3 at 12:59 PM

Lantheus holders would get $102.50 per share in cash plus up to $12 more if sales targets are met by 2030. Source: Finimize $RADX $LNTH https://finimize.com/content/curium-agrees-to-buy-lantheus-in-an-8-billion-radiopharma-deal

0 · Reply

RadioIsotope25 Aug. 3 at 12:50 PM

$RADX Bracco aImaging acquired similar agent for $450 million with only $150 million in sales. Why wouldn’t they want to acquire RAD101 for $100 million and spend $26 million on phase three trial and make $600 million a year?

0 · Reply

Lalalilala Aug. 3 at 8:17 AM

$RADX My friends, you need to be resilient and not give in to panic! The further it falls, the more I think pressure is being put on small investors to sell their portfolios before something big is announced in the coming quarter. I'm going to start buying again this Monday at the opening bell.

1 · Reply

RadioIsotope25 Aug. 2 at 8:41 PM

Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement. Source: PharmaVoice $RADX https://www.pharmavoice.com/news/telix-radiopharma-deal-regeneron-drug-pharma/826503/

0 · Reply

RadioIsotope25 Aug. 2 at 3:28 PM

Potential Comp and Buyer: Molecular PET agent developer Blue Earth Diagnostics has been picked up by the Italian multinational Bracco, which will take in the company as a subsidiary unde… Source: Fierce Biotech $RADX https://www.fiercebiotech.com/medtech/blue-earth-diagnostics-sold-to-bracco-imaging-450m-deal

0 · Reply

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	10,245
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	Strong Buy
Price Target	N/A